CONTEXT: We studied two families from Galicia (northwest Spain) with Pendred syndrome (PS) and unusual thyroid phenotypes. In family A, the proposita had a large goiter and hypothyroxinemia but normal TSH and free T3 (FT3). In family B, some affected members showed deafness but not goiter. OBJECTIVE: Our objective was to identify the mutations causing PS and molecular mechanisms underlying the thyroid phenotypes. INTERVENTIONS: Interventions included extraction of DNA and of thyroid tissue. PATIENTS: Propositi and 10 members of the two families participated in the study. MAIN OUTCOME MEASURES: Main outcome measures included SLC26A4 gene analysis, deiodinase activities in thyroid tissue, and c.416-1G-->A effects on SLC26A4 splicing. In addition, a primary PS thyrocyte culture, T-PS2, was obtained from propositus B and compared with another culture of normal human thyrocytes, NT, by Western blotting, confocal microscopy, and iodine uptake kinetics. RESULTS: Proposita A was heterozygous for c.578C-->T and c.279delT, presented with goiter, and had normal TSH and FT3 but low FT4 attributable to high type 1 and type 2 iodothyronine deiodinase activities in the goiter. Propositus B bore c.279delT and a novel mutation c.416-1G-->A; some deaf relatives were homozygous for c.416-1G-->A but did not present goiter. The c.279delT mutation was associated with identical haplotype in the two families. T-PS2 showed truncated pendrin retained intracellularly and high iodine uptake with low efflux leading to iodine retention. CONCLUSIONS: c.279delT is a founder mutation in Galicia. Proposita A adapted to poor organification by increasing deiodinase activities in the goiter, avoiding hypothyroidism. Lack of goiter in subjects homozygous for c.416-1G-->A was due to incomplete penetrance allowing synthesis of some wild-type pendrin. Intracellular iodine retention, as seen in T-PS2, could play a role in thyroid alterations in PS.
CONTEXT: We studied two families from Galicia (northwest Spain) with Pendred syndrome (PS) and unusual thyroid phenotypes. In family A, the proposita had a large goiter and hypothyroxinemia but normal TSH and free T3 (FT3). In family B, some affected members showed deafness but not goiter. OBJECTIVE: Our objective was to identify the mutations causing PS and molecular mechanisms underlying the thyroid phenotypes. INTERVENTIONS: Interventions included extraction of DNA and of thyroid tissue. PATIENTS: Propositi and 10 members of the two families participated in the study. MAIN OUTCOME MEASURES: Main outcome measures included SLC26A4 gene analysis, deiodinase activities in thyroid tissue, and c.416-1G-->A effects on SLC26A4 splicing. In addition, a primary PS thyrocyte culture, T-PS2, was obtained from propositus B and compared with another culture of normal human thyrocytes, NT, by Western blotting, confocal microscopy, and iodine uptake kinetics. RESULTS:Proposita A was heterozygous for c.578C-->T and c.279delT, presented with goiter, and had normal TSH and FT3 but low FT4 attributable to high type 1 and type 2 iodothyronine deiodinase activities in the goiter. Propositus B bore c.279delT and a novel mutation c.416-1G-->A; some deaf relatives were homozygous for c.416-1G-->A but did not present goiter. The c.279delT mutation was associated with identical haplotype in the two families. T-PS2 showed truncated pendrin retained intracellularly and high iodine uptake with low efflux leading to iodine retention. CONCLUSIONS:c.279delT is a founder mutation in Galicia. Proposita A adapted to poor organification by increasing deiodinase activities in the goiter, avoiding hypothyroidism. Lack of goiter in subjects homozygous for c.416-1G-->A was due to incomplete penetrance allowing synthesis of some wild-type pendrin. Intracellular iodine retention, as seen in T-PS2, could play a role in thyroid alterations in PS.
Authors: O Gonzalez Trevino; O Karamanoglu Arseven; C J Ceballos; V I Vives; R C Ramirez; V V Gomez; G Medeiros-Neto; P Kopp Journal: Eur J Endocrinol Date: 2001-06 Impact factor: 6.664
Authors: L A Everett; I A Belyantseva; K Noben-Trauth; R Cantos; A Chen; S I Thakkar; S L Hoogstraten-Miller; B Kachar; D K Wu; E D Green Journal: Hum Mol Genet Date: 2001-01-15 Impact factor: 6.150
Authors: L Fugazzola; D Mannavola; N Cerutti; M Maghnie; F Pagella; P Bianchi; G Weber; L Persani; P Beck-Peccoz Journal: J Clin Endocrinol Metab Date: 2000-07 Impact factor: 5.958
Authors: Julie P Taylor; Russell A Metcalfe; Philip F Watson; Anthony P Weetman; Richard C Trembath Journal: J Clin Endocrinol Metab Date: 2002-04 Impact factor: 5.958
Authors: N López-Bigas; S Melchionda; R de Cid; A Grifa; L Zelante; N Govea; M L Arbonés; P Gasparini; X Estivill Journal: Hum Mutat Date: 2002-07 Impact factor: 4.878
Authors: Vanessa C S de Moraes; Emanuele Bernardinelli; Nathalia Zocal; Jhonathan A Fernandez; Charity Nofziger; Arthur M Castilho; Edi L Sartorato; Markus Paulmichl; Silvia Dossena Journal: Mol Med Date: 2016-01-04 Impact factor: 6.354
Authors: Andrea M Oza; Marina T DiStefano; Sarah E Hemphill; Brandon J Cushman; Andrew R Grant; Rebecca K Siegert; Jun Shen; Alex Chapin; Nicole J Boczek; Lisa A Schimmenti; Jaclyn B Murry; Linda Hasadsri; Kiyomitsu Nara; Margaret Kenna; Kevin T Booth; Hela Azaiez; Andrew Griffith; Karen B Avraham; Hannie Kremer; Heidi L Rehm; Sami S Amr; Ahmad N Abou Tayoun Journal: Hum Mutat Date: 2018-11 Impact factor: 4.878
Authors: D Calebiro; P Porazzi; M Bonomi; S Lisi; A Grindati; D De Nittis; L Fugazzola; M Marinò; G Bottà; L Persani Journal: J Endocrinol Invest Date: 2010-09-09 Impact factor: 4.256
Authors: Philine Wangemann; Hyoung-Mi Kim; Sara Billings; Kazuhiro Nakaya; Xiangming Li; Ruchira Singh; David S Sharlin; Douglas Forrest; Daniel C Marcus; Peying Fong Journal: Am J Physiol Renal Physiol Date: 2009-08-19
Authors: Dona M Kanavy; Shannon M McNulty; Meera K Jairath; Sarah E Brnich; Chris Bizon; Bradford C Powell; Jonathan S Berg Journal: Genome Med Date: 2019-11-29 Impact factor: 11.117